{"name":"Basking Biosciences, Inc.","slug":"basking-biosciences-inc","ticker":"","exchange":"","domain":"basking.com","description":"Basking Biosciences, Inc. is a biotechnology company focused on the development of innovative therapies across various therapeutic areas. The company's pipeline includes three drug candidates, with BB-025 and DTRI-031 in Phase 1 and BB-031 in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BB-025","genericName":"BB-025","slug":"bb-025","indication":"Other","status":"phase_1"},{"name":"DTRI-031","genericName":"DTRI-031","slug":"dtri-031","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BB-031","genericName":"BB-031","slug":"bb-031","indication":"Metastatic breast cancer","status":"phase_2"}]}],"pipeline":[{"name":"BB-025","genericName":"BB-025","slug":"bb-025","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BB-031","genericName":"BB-031","slug":"bb-031","phase":"phase_2","mechanism":"BB-031 is a small molecule that targets the PI3K pathway.","indications":["Metastatic breast cancer"],"catalyst":""},{"name":"DTRI-031","genericName":"DTRI-031","slug":"dtri-031","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNVktTTE51YVFoV2xoY1hYY1NkazQzYXVnWWFHamNvOV9INFhNZUdWZGlzMjlHZTRuRjZjTEt4c0VFYktSRFBKWmVidDQ4bHdQOEcwcy1lWXlGRG1XZGdYeHl6aUM3cEVHQzZTRjJiWkthQk5ISDZpZW9MWXFCaEdubGJuTFR0WVo4?oc=5","date":"2026-03-02","type":"pipeline","source":"Yahoo Finance","summary":"Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight - Yahoo Finance","headline":"Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQbE82UlRsbVJlLU5kQXRRRGRDZ3c3M3hORVg5TWNJQ3ZPZ2VDRUFGUG5uSjRSMU9DZkI0SHFIOGNmNUlXMjMtU3RPX3phcEVGZGNwZVA3dkxGdExoTlFFZ3B3TFlYRUFvR29EN0dwaWpHZDM3cVJzeVItbzBmdkRGczBMTWJVaFZlZkNQck9UMmZyVG02VHBhOERGWkxpY2RVb0xxeElUcVpWZTlVckYwTEROakJxa0JIUU5ySFFyZw?oc=5","date":"2026-01-22","type":"pipeline","source":"Bloomberg.com","summary":"Llamas Are Big Pharma’s Secret Weapon to Find New Drugs - Bloomberg.com","headline":"Llamas Are Big Pharma’s Secret Weapon to Find New Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxONG40UEdmd0pNWENBQjdZTUxQVFJDU1NOWmNVenV1VUtlbG9pSmRoN2gwNkVlT25SY2tUMmt4OVNHejFtQmpqbUR6YmpwaFBHMFJGU0J1MjNMZnFPU0FMZC1qMGE1OXAwR2M2NDVZODVyOHNVUE1Wdk0ybHhER1djVDJCdV9pR3JmbWwyUGhGcVNIV2d2QTF4cTZQLWpQemRUQW5GMDJhYkNJby1IUnh0a2dwTVAxUF85Y1NpbTBHYlNjMF9nWFhJY3BkbVJudnZnbWY1YXFqb21hQ0RwVUNVNnk1d0xVVHVPTDg0bXREMWNWbmZidEViSmdMNE1KLTJ2am56blBQNzhOZFhMc3ItRmF0N3JRdWN0Y1ItZEJGRjRHLVM4dWNOQnc3S0JCZmgwZlVzcw?oc=5","date":"2025-11-12","type":"trial","source":"PR Newswire","summary":"Basking Biosciences Announces First Participants Dosed in Phase 1 Study of BB-025, a Direct-Acting Reversal Agent for Investigational Stroke Therapy BB-031 - PR Newswire","headline":"Basking Biosciences Announces First Participants Dosed in Phase 1 Study of BB-025, a Direct-Acting Reversal Agent for In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNZUlhZlJFbzdrWEc3YWMtekRvczN4MXpSSkZmMmc2X0JvLWJRenZRcVdlek8xZVptVmFJU2dhVGdPQk9ndmJFNnRHOWF6TFVVQnFHOTM0Z0p1RVE3a0JwYkVjb3BFY1czTS1ZSlhVdTYxbmtnSURKMXZYWWxvWlQ4X0hRVlUxWEZGWUplcWJn?oc=5","date":"2025-10-30","type":"pipeline","source":"Medical Marketing and Media","summary":"The Escalator: Organon, Kenvue, Real Chemistry and more - Medical Marketing and Media","headline":"The Escalator: Organon, Kenvue, Real Chemistry and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNTElBeE42NnlmVDVXb0dFMklGQkFhR3hGRTJqcy1WbDJYN3NNN2xIcVJ3Z0tPTXlXekJyNy1BZWlDa2FFdGpEd3pCbWllQzI1M291T3JiTmNSNUZCWFhKUjU1Zy1OV0tfM0ItTVhhZWkxaW9vVUVvVnJCRkxXdmczVnE1NTIyZXpFMkUyaEo2ZV9kMlNkUXltQnVkMS1TLXB3ZW4xR3dIWUJoMHhrLWdR?oc=5","date":"2025-10-22","type":"trial","source":"dicardiology.com","summary":"Basking Biosciences Phase 2 Stroke Trial Progresses; Company Names New CEO - dicardiology.com","headline":"Basking Biosciences Phase 2 Stroke Trial Progresses; Company Names New CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOLV9iUk5NYzA1ZjFubjVGSWRWaWNfeDkzczRseUZfeE5VaVc4ZzN0S3pyMkFzQUdXR2VlcG1vZG5zdVdvNFB6d0g1Z0lSZXdvQnl5cXU0Q1dLV2tsbmx6Nkp6SldRS1RwZGJRMmpWb19fNHU3UU9OanZtOGNOVEdlWXNuRmNxWU9VMV9Ga0pSQjZjSE4yS3JFTg?oc=5","date":"2025-10-22","type":"pipeline","source":"Contract Pharma","summary":"Basking Biosciences Names Dr. Julia Owens as CEO - Contract Pharma","headline":"Basking Biosciences Names Dr. Julia Owens as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxPcGJhLU5rNng0VEM0OHRmLVdZd3hScFRsajhadF9yZ0dRb1l2cEQ0SWRRLXpFMm5MVndENHdINjUwUFQtTm1zNkFSNERXczdLeTlNNzFlal9VeF9qcUxoSW1EeXFYN05hMjdRWXZTZ3ZuX2RPOXpseXZRMU90c2pmNDgxa0NSVG5FQXIwRE5OMmZpTWtRcXI2cHk5U2RmNVhKcV9kTDBGbURleVZtS29zcnJRSkhRVzZUSjY5RE5GT3lxWmY5b2hDYU1pd0xtZGhEV1JJSkgyd0l5ZXR3TTV4M1ltUVpSVXVvRWNWeUxYZkMtVHBVWHQ1SUc2RUJ0UlRPdmxIcThvQjBxNEZqOHdrRkdyem5JbGlWUEZVMXpyTFdwX1ZmSXZsOVd3M3ZlSjJxaER5QWs5eUdqRG4tWTdVVVNtb1hlR3pXS2dz?oc=5","date":"2025-10-22","type":"trial","source":"PR Newswire","summary":"Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and Appoints Julia C. Owens, Ph.D. as Chief Executive Officer - PR Newswire","headline":"Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1oT3VEMEJOYXRfUGlmampnQy1TZWtXUzNwd3NFZEZUcXJXRW1DMkpGUEFQTGlnUmV5MWxfUmpPYU1IN0VJczdnTE5JNkgzVm9UYmcxSGZ1S2h4ZjllMk9tVWhqQ3h4Q1p0Z2xNeFItOWlzRy1C?oc=5","date":"2025-10-09","type":"pipeline","source":"BioSpace","summary":"9 Companies Hiring in Oncology - BioSpace","headline":"9 Companies Hiring in Oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQRFNUZjhodWloUTVSc1F4REJPMGwydTg2akdRRWxGVEN1S3NKd2VtY2NxT1c4bmVPVFV4V0RDdGVHc2NEMkw0NUU5T1pDMWx4bmpVZXhmNG1xUzVqUlJDeVJtTzhoZjRRcFlpRWY3WUl6MTNwdW9JVEl3R2lyd09IeWdQYWlCX1lfamh4LUNiY21SZmpzME8wLVdRYURBWUUxS3MxWlFLZ1NNQWltbmtTeGlYNjM?oc=5","date":"2024-02-05","type":"pipeline","source":"The Business Journals","summary":"Ohio State-Duke spinoff Basking Biosciences raises $55M to test stroke treatment - The Business Journals","headline":"Ohio State-Duke spinoff Basking Biosciences raises $55M to test stroke treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOMmV6djFzVy1DbUF1aGhpTVZzYnVuOG1oNW5fY1RDLUdGLXZTcld5OWlIOFQ5VlFIbFBLTGtEUkp0dXV3VV9vcTJmMFFvRjlJZWp5WDBRY0N6M2NxWGNxNkpYMEF0MUwwbzA0SlU5M0xxMk85Z0VLTjVKczRHa2x1VmhHS3FjSjlTNXNXVE1PRmdyam5CRndSYVZ1OWpITUtBbVNNTlE2aHRWU0tRQ2R6VVpJcGdvaUVQZE5oTHh0RFFtbzRac1pwRkt0ZlZEaV9lWUN2NkVJNFJvaGNQVXNFdXE0YWJMb0JZd2xCZnRGdjBsYjFnUzdYZWJTSXhlT0RzbVd5T3N4NW5jSHdjMHJ5RW5NQWFnTW1aRzV6ajNSc05qSkVPNW40WGxwMUo0Y1hnTGc?oc=5","date":"2024-02-01","type":"pipeline","source":"Business Wire","summary":"Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke - Business Wire","headline":"Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxONjI2THYyOU9rbVhMMDRXU1JWNF9zcjRaT0R2TXR3SU5iQTktN1FYTlY1YzQzSkstRVFGZGxsOWg1RThVWENZTkRmemYyMEhBZzZFWUJZZ2h1YVJzN1NKaVpBSmMzWEU0TXlUbVhaZ0JtLTZDZmxiM1JEU1dBcU1PMg?oc=5","date":"2024-01-04","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxQcllwcTI4WmZzc3Z3dFZSbE1PdDJESHY2V1ZiNEhfYW41aTZnbkdpTjhtNUVXV0JUOVk5R21Zem9MSXVtODR2dkZCb2dfOHhYYjJPTmtRTE9iWEtMZzN3LW9ULU9zdks3OW9FdkNKalEzdkc5bEdVcXU4R0FJR2g5SWFXTFU2Q29aUThmdHowOWI2YmxrMDZlM0ZucW1DdWpjMDJQdEk0S0lJaEVVc1M0U3JRdTU0LTNpZ1BIb1NSdGNERmJQUm1DN2l5QWdfM25VWlRna2hIQkxZNTVJYnJkSnFGYVhWVy1QVlhkZWliVGV1eXpfRi1GOXdOejRLNG0tanN2T0p6SEJsY2dpZDMxUnpSeXBGdw?oc=5","date":"2022-09-15","type":"deal","source":"GlobeNewswire","summary":"Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics - GlobeNewswire","headline":"Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}